- Home
- SDHY vs AMLX Comparison
SDHY vs AMLX Comparison
Compare SDHY & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- AMLX
- Stock Information
- Founded
- SDHY 2020
- AMLX 2014
- Country
- SDHY United States
- AMLX United States
- Employees
- SDHY N/A
- AMLX N/A
- Industry
- SDHY Finance/Investors Services
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- SDHY Finance
- AMLX Health Care
- Exchange
- SDHY Nasdaq
- AMLX Nasdaq
- Market Cap
- SDHY 409.3M
- AMLX 481.9M
- IPO Year
- SDHY N/A
- AMLX 2022
- Fundamental
- Price
- SDHY $16.56
- AMLX $3.30
- Analyst Decision
- SDHY
- AMLX Buy
- Analyst Count
- SDHY 0
- AMLX 7
- Target Price
- SDHY N/A
- AMLX $7.60
- AVG Volume (30 Days)
- SDHY 94.0K
- AMLX 748.4K
- Earning Date
- SDHY 01-01-0001
- AMLX 03-04-2025
- Dividend Yield
- SDHY 8.46%
- AMLX N/A
- EPS Growth
- SDHY N/A
- AMLX N/A
- EPS
- SDHY 1.07
- AMLX N/A
- Revenue
- SDHY N/A
- AMLX $196,485,000.00
- Revenue This Year
- SDHY N/A
- AMLX N/A
- Revenue Next Year
- SDHY N/A
- AMLX N/A
- P/E Ratio
- SDHY $14.31
- AMLX N/A
- Revenue Growth
- SDHY N/A
- AMLX N/A
- 52 Week Low
- SDHY $13.93
- AMLX $1.58
- 52 Week High
- SDHY $15.50
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- SDHY 52.54
- AMLX 39.44
- Support Level
- SDHY $16.51
- AMLX $3.42
- Resistance Level
- SDHY $16.65
- AMLX $3.65
- Average True Range (ATR)
- SDHY 0.10
- AMLX 0.26
- MACD
- SDHY -0.01
- AMLX 0.00
- Stochastic Oscillator
- SDHY 43.48
- AMLX 2.94
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.